Department of Public Health, Shihezi University School of Medicine, Shihezi 832000, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Shihezi University School of Medicine, Shihezi 832000, China.
Nutrients. 2022 Jun 7;14(12):2361. doi: 10.3390/nu14122361.
In 2020, a group of international experts proposed a new term ‘metabolic dysfunction-associated fatty liver disease’ (MAFLD) to replace ‘non-alcoholic fatty liver disease’. This study aimed to describe the epidemic characteristics of MAFLD, incidence of cardiovascular disease (CVD), and relationship between MAFLD and incident CVD. In 2016, 12,794 Uyghur adults from Kashgar, Xinjiang, were grouped according to the presence or absence of MAFLD. The primary outcome was the occurrence of CVD events. Fatty liver was diagnosed using ultrasound. The prevalence of MAFLD was 16.55%. After excluding patients with previous CVD, 11,444 participants were followed up for a median period of 4.7 years. During the follow-up period, the overall CVD incidence was 10.40% (1190/11,444). The incidence of CVD in the patients with MAFLD was significantly higher than that in the non-MAFLD patients (18.38% vs. 9.02%, p < 0.001; multivariable-adjusted hazard ratio = 1.37, 95% CI = 1.20−1.56). The prevalence of MAFLD was relatively low, whereas the incidence of CVD was relatively high among the Uyghur adults in rural Xinjiang. Individuals with MAFLD have a higher risk of developing CVD independent of traditional cardiovascular risk factors, obesity, type 2 diabetes mellitus (T2DM), and dyslipidaemia.
2020 年，一组国际专家提出了一个新术语“代谢相关脂肪性肝病（MAFLD）”来取代“非酒精性脂肪性肝病”。本研究旨在描述 MAFLD 的流行特征、心血管疾病（CVD）的发生率以及 MAFLD 与 CVD 事件发生之间的关系。2016 年，根据是否存在 MAFLD，将新疆喀什的 12794 名维吾尔族成年人进行分组。主要结局是 CVD 事件的发生。使用超声诊断脂肪肝。MAFLD 的患病率为 16.55%。排除有既往 CVD 的患者后，对 11444 例患者进行了中位随访时间为 4.7 年的随访。随访期间，总体 CVD 发生率为 10.40%（1190/11444）。MAFLD 患者的 CVD 发生率明显高于非 MAFLD 患者（18.38%比 9.02%，p<0.001；多变量调整后 HR=1.37，95%CI=1.20−1.56）。维吾尔族农村成年人 MAFLD 的患病率相对较低，但 CVD 的发病率相对较高。患有 MAFLD 的个体发生 CVD 的风险高于无 MAFLD 的个体，且独立于传统心血管危险因素、肥胖、2 型糖尿病（T2DM）和血脂异常。
